properties of a crude saponin fraction (GF-DS-I) and saponins (GF-DS-II) which were obtained from Panax Ginseng leaves, were estimated by blind screening consisting of three tests : 1) neuropharmacological observations in mice, 2) tests on the respiratory and cardiovascular system in rats, and 3) tests on the guinea-pig isolated ileum. GF-DS-I appeared to have CNS-depressive, neuroleptic, analgesic, hypertensive, cholinergic, and histamine-like activities, while GF-DS-II, had CNS-depressive, neuroleptic, analgesic, hypotensive, atropine-like and papaverine-like activities. These neuroleptic activities, were examined and confirmed by tests on motor activity, exploratory movements, muscle tone, motor coordination, hypothermia and potentiation of CNS-depressant, and pole climbing, anticonvulsant and analgesic tests. No effects were seen on hemolysis.
Pharmacological studies on extracts of Ginseng root, have been reported by a number of investigators (1-9), but a report on Ginseng leaves has not heretofore been seen. Chemical research on Ginseng leaves has been reported by Shibata et al. (10, 11) . We have investigated Ginseng root systematically, and, in particular, pharmacological properties of saponins in Ginseng root. A crude saponin fraction (G. No. 3) and GNS being a mixture of neutral saponins consisting mainly of Ginsenoside-Rb1, -Rb2 and -Rc have been reported, in particular the pharmacological properties (12) (13) (14) (15) . In this paper, pharmacological properties of Ginsenoside-F (GF), the main component of Ginseng leaves has been studied, and compared with those of saponin fractions from Ginseng root.
MATERIALS AND METHODS

Preparation of extracts from Ginseng leaves
Ginseng leaves were treated as shown in Fig. 1 , and GF-DS-I (crude saponin fraction) and GF-DS-II (saponins prepared from GF-DS-I) were used. On acid hydrolysis, GF-DS-II afforded panaxadiol and panaxatriol.
Details of the fractionation of these components from Ginseng leaves, is described by Shibata et al. (10, 11) . The solution of these two components was dissolved in physiological saline.
The following methods were employed.
1) Neuropharmacological observations in mice
This method modified by Takagi et al. (16) , is based on the work of Irwin (17 2) Acute toxicity in mice LD50 of GF-DS-I and II (i.v.) was 381 and 299 mg/kg respectively. Behavioral changes observed in lethal doses : GF-DS-I produced extended posture with abdomen touching floor and abnormal gait a few min after treatment. A sedative state was seen for several min. Approx. 10 min later, swimming convulsions appeared and mice died after 15 to 25 min. GF-DS-II produced these behavioral changes faster than GF-DS-I and mice died within several min. LD50 (i.p.) was 402 and 306 mg/kg respectively, and oral LD50 was estimated to be more than 5g/kg. Surviving mice showed no change in behavior the following day.
3) Tests on the respiratory and the cardiovascular systems in the rat GF-DS-I: The arterial blood pressure of the rat lowered transiently with i.v. injection of GF-DS-I in doses between 0.5 and 2.0 mg/kg, and rose transiently with more than 5 mg/kg as shown in Fig. 3 . One mg/kg lowered the mean arterial blood pressure by 12% that of normal however 5 mg/kg raised it by 9 %, in 5 rats respectively. A slight decrease in heart rate was also detected in doses of more than 1 mg/kg, but effect was not seen on respiration after these doses. Tachyphylaxis was not detected with an injec- 
GF-DS-II:
The arterial blood pressure showed a prolonged hypotension with injection of GF-DS-II at a dose of more than 2 mg/kg (Fig. 3) . In 5 rats, 10 mg/kg lowered the mean arterial blood pressure by 24 % that of normal. Effects on respiration and heart rate were not seen after these doses. Characteristic blood pressure responses produced by the above five stimuli were not altered. Pre-administration of Atr, Diph and Prop did not eliminate the hypotensive response to GF-DS-II in 5 rats.
4)
Tests on the guinea-pig isolated ileum GF-DS-I caused contractions of the ileum in high concentrations (10-5-10-4 g/ml). The contraction produced at 10 g/ml was completely inhibited by Atr and partially by Diph. High concentration (10-4 g/ml) of GF-DS-I induced significant inhibition of the contraction caused by ACh and His in higher concentrations. Effects on 5-HT and Nic contractions were not seen (Fig. 4-1) . GF-DS-II produced no contraction, and inhibited ACh, His, 5-HT and Nic contractions in higher concentrations (10-5-10-4 g/ml) (Fig. 4-2) .
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FIG. 4-1. Effect of GF-DS-I
on guinea pig isolated ileum. (Fig. 6-1) .
FIG. 4-2. Effect of GF-DS-II
ii) Hole cross test: Twenty mg/kg of GF-DS-II given i.p. produced a significant decrease of exploratory movement by approx. 39 % that of control ( Fig. 6-2 ). The inhibition of exploratory movement was recognized at a dose of 50 mg/kg immediately after administration and continued for a few hr.
9) Climbing test in mice
GF-DS-I in a dose of more than 12.5 mg/kg, and GF-DS-II in a dose of more than 25 mg/kg, produced a significant inhibition of this exploratory behavior (Fig.7) , which was quite evident 30 min after administration. and II (P<0.05) ( Table 2) .
ii) Tail pressure test: Significant increase of maximum pain threshold was seen in a dose of 400 mg/kg of GF-DS-I and over 100 mg/kg of GF-DS-II (Fig.8) .
Maximal effect was seen 30 min after administration.
12) Anticonvulsant tests in mice i) Convulsions induced by electroshock:
GF-DS-I and II had no inhibitory effect on tonic flexor, tonic extensor, clonic convulsions and mortality. ii) Convulsions induced by chemicals: GF-DS-I in a dose of 200 mg/kg elongated the time leading to clonic and tonic extensor convulsions and to death induced by strychnine.
Two hundred mg/kg of GF-DS-II also elongated the time leading to these effects but not significantly ( Table 3 ). The time leading to clonic and tonic extensor convulsions induced by pentylenetetrazol was elongated by GF-DS-II in a dose of 100 mg/kg. Decrease of mortality was also seen after this dose (Table 3 ).
13) Hypothermia in mice
Significant lowering of rectal temperature was seen in a dose 400 mg/kg of GF-DS-I and II 30 min after administration and continued for 2 hr. 200 mg/kg also lowered the rectal temp. 30 min after administration, however not significantly.
14) Ratio of reflexes in the mouse
No change was seen on the corneal reflex for 2 hr after administration of GF-DS-I and IL Disappearance of pinna reflex could be observed in 2 animals on 200 mg/kg of GF-DS-II, 9 animals on 400 mg/kg, and 7 animals on 400 mg/kg of GF-DS-I, 1 hr after administration and continued for 2 hr.
15) Pole climbing test in rats
GF-DS-II in doses of 10 and 30 mg/kg produced a significant specific block of the CR and elongation of response latency (P<0.01), within 40 min after administration.
Maximal effects were produced within 10 min after treatment, and effects on the CR and response latency were not seen until 100 min after. 90 mg/kg showed a significant block of the unconditioned response 20 min after the treatment and continued for 2 hr. Two animals died 3 days after the treatment (Fig. 9 ).
16) Motor incoordination in rats
Groups of 8 male rats, weighing 150-180 g, were used and GF-DS-II was injected i.p.
i) Rotating rod test: 10 and 30 mg/kg produced no effect on motor deficit and 90 mg/kg produced a slight inhibition for 1 hr after administration. Maximal effect was seen in the first trial 30 min after injection. 180 mg/kg produced a significant inhibition for 2 hr after administration.
ii) Suspension test: 30 mg/kg produced a slight muscle relaxation within 30 min after administration but no effect was seen 90 min later. 90 and 180 mg/kg produced a significant decrease of muscle tone for 2 hr after treatment. Loss of pinna, corneal and righting reflexes was not seen for 2 hr. Neuroleptic properties were examined using the tests as shown in this paper. GF-DS-I and II produced CNS-depression as revealed by their effects on reduction of spontaneous and exploratory movements and potentiation of hypnotic action of hexobarbital.
These effects occurred with doses which did not produce motor incoordination and muscle relaxation in mice. Analgesic and anticonvulsant activities were also confirmed. Moreover, GF-DS-II inhibited conditioned avoidance response in the pole climbing test. The specific blocking effect on CR was transient and appeared 1 hr after administration. The inhibition of CR induced by GF-DS-II occurred within doses which did not produce depression of motor coordination and muscle tone. 90 mg/kg of GF-DS-II inhibited unconditioned response and produced a significant decrease of grip tone in rats. In addition to these actions, results from rotating rod test, hypothermia and ratio of two reflexes strongly indicate neuroleptic activity of GF-DS-II.
In previous reports (12) (13) (14) , it was proposed that G.No.3 extracted from Ginseng root and containing mainly neutral saponins (GNS) and other components, had possible tranquillizing, cholinergic, histamine-like, papaverine-like and hypertensive activities, and that tranquillizing and papaverine-like activities were ascertained in GNS isolated from G.No.3 and consisted mainly of neutral saponins, Ginsenoside-Rbi, -Rb2 and -Rc. Neuroleptic activity of G.No.3 and GNS was also confirmed (13, 14) . Similarities in pharmacological properties were observed between GNS and GF-DS-II, and between G.No.3
and GF-DS-I. It was confirmed that Ginsenoside-Rg, the saponins from Ginseng root, which afforded panaxatriol on acid hydrolysis, does not have CNS-depressive activity.
Neuroleptic activity of GF-DS-II is attributed to neutral saponins which are similar to main components of GNS and afforded panaxadiol on acid hydrolysis.
